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Humic acids are natural constituents of soil and ground water and mainly consist of mixtures of polycyclic phenolic
compounds. A similar complex of compounds with a mean size of about 1000 Da, designated HS-1500, was synthesized
by oxidation of hydroquinone. HS-1500 inhibited HIV-1 infection of MT-2 cells with an IC50 of 50–300 ng/ml and showed a
mean cell toxicity of about 600 mg/ml. Inhibition of HIV-induced syncytium formation was observed at 10–50 mg/ml.
Treatment of free and cell-attached HIV with HS-1500 irreversibly reduced its infectivity, whereas the susceptibility of target
cells for the virus was not impaired by treatment prior to infection. The HIV envelope protein gp120SU bound to sepharose-
coupled HS-1500 and could be eluted by high salt and detergent. HS-1500 interfered with the CD4-induced proteolytic
cleavage of the V3 loop of virion gp120SU. Furthermore, binding of V3 loop-specific antibodies was irreversibly inhibited,
whereas binding of soluble CD4 to gp120SU on virus and infected cells was not affected. In conclusion, our data suggest,
that the synthetic humic acid analogue inhibits the infectivity of HIV particles by interference with a V3 loop-mediated step
of virus entry. q 1996 Academic Press, Inc.
The progression of the HIV infection toward AIDS ap- inactivating capacity at 47 for at least three months. The
compound is related to the previously described polyhy-pears to be correlated to the virus burden which is sus-
tained by continuously high virus replication and reinfec- droxy-carboxylates (PHCs) by its complexity, basic chem-
ical structure, and functional groups (11). However, HS-tion of target cells (1, 2). Thus, virus-receptor binding and
internalization represent promising targets for antiviral 1500 is distinct from the group of PHCs by its lower mean
molecular mass, a significantly higher efficiency againsttherapy. Antibodies to the viral envelope proteins,
gp120SU and gp41TM (3, 4), to the receptor CD4 as well HIV-1, and an inhibition mechanism that mainly affects
as soluble forms of the receptor itself (5) inhibit primary virus–cell fusion.
steps of infection in vitro. Yet the type-specificity of V3 We have first observed the inhibitory potential of HS-
loop-reactive neutralizing antibodies (6, 7) and the low 1500 in a syncytium assay with MT-2 cells (12). The po-
efficiency of soluble CD4 against primary virus isolates tential mode of inhibition was elucidated by inhibition of
(8) limit their therapeutic applicability. In contrast, polyan- virus antigen production and the demonstration of direct
ionic compounds with various chemical structures inhibit influence of HS-1500 on the fusion of infected with unin-
a broader spectrum of HIV subtypes (9). Here we report fected MT-2 cells. The inhibitory concentrations in these
on the inhibition of HIV-1 by HS-1500, a stable complex assays, which were derived from repeated dose re-
that was synthesized by oxidation of hydroquinone at sponse experiments (not shown) are summarized in Ta-
high pH as described in the European patent No. 0 537 ble 1. Upon pretreatment of virus and continuous pres-
430 B1. HS-1500 consists of aliphatically linked phenolic ence of HS-1500 an inhibitory concentration 50 (IC50) of
rings with carboxylic functional groups. The pattern of 0.3 mg/ml was observed in the syncytium assay. The
bands obtained by isoelectric focussing of HS-1500 was complete inhibition at 10 mg/ml appeared to be irrevers-
remarkably similar to that of natural humic acid com- ible, since syncytium formation was not resumed, when
plexes (10). The lyophilized product has a virtually unlim- cells of the completely protected microcultures were fur-
ited shelf life. Neutral aqueous solutions retain their virus ther subcultured in the absence of HS-1500 for up to 50
days. In the virus antigen assay, an IC50 of 0.05 mg/ml
was observed, indicating inhibition of virus production.1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 0761-203-6639. E-mail: schf@sun1.ukl.uni-freiburg.de. Fusion of infected with uninfected MT-2 cells was sup-
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TABLE 1 activity by more than 50% as compared to the virus stock
that was sedimented without prior treatment. HS-1500Efficient Inhibition of HIV-1 in Cell Culture by HS-1500
could not be concentrated by sedimentation. Because
almost the same IC50 was observed, when cells and virusAssay Syncytiaa Antigenb Cell fusionc
were treated simultaneously for 5 days (Table 1), we are
IC50 [mg/ml] 0.3 0.05 10–30 tempted to conclude that HS-1500 rapidly inactivated the
IC90 [mg/ml] 2–5 0.3 50–100 HIV particle in an irreversible mode. Thus, the virion ap-
peared as the primary and most sensitive target. Inhibi-a 1.25 1 104 MT-2 cells (33) were incubated in triplicate for 5 days
tion of syncytium formation by continuous presence ofwith 150 syncytium-inducing units of HIV-1IIIB from H9 cells (34) and
appropriate dilutions of HS-1500 in the wells of microtiter plates. Dose HS-1500 in the cell culture can be explained by inactiva-
response curves were obtained by counting of syncytia with an inverted tion of the virus, because it follows the same dose re-
microscope 5 days later. sponse as the inactivation of cell-free virus. Inactivationb Inhibition of virus replication was measured in the cell-free super-
of the input virus would also suffice to explain suppres-natant by the p24 core protein ELISA (DuPont).
sion of virus antigen production.c To determine syncytium formation by fusion of infected with unin-
Pretreatment of MT-2 cells with HS-1500 concentra-fected lymphocytes, 10% of HIV-1IIIB-infected and 90% of uninfected MT-
2 cells were cocultivated for 2 days with varying concentrations of HS- tions of 1.5 to 44 mg/ml and washing prior to infection
1500 before syncytia counting. resulted in a 20–30% increase of syncytium formation
(data not shown). Therefore, CD4 and other cell surface
structures relevant for virus attachment and entry are notpressed with an IC50 of 10–30 mg/ml and completely
significantly involved in the inhibition by HS-1500.inhibited at 300 mg/ml. Thus, for direct interference with
HIV-induced cell fusion about 30- to 100-fold more HS-
1500 was needed than for inhibition of fusion as a conse-
quence of infection by free virus. The differences in the
two syncytium assays suggest that incubation of HIV with
HS-1500 may affect an early step of the virus replication
cycle, which is more sensitive to the synthetic humate,
than the virus-induced syncytium formation itself. Similar
differences have been observed with other inhibitors (13,
14). HIV-induced cell fusion may be less sensitive to
inhibition by HS-1500 because of the higher multiplicity
of g120-CD4 interactions and additional cellular proteins
such as LFA-1 that are exclusively involved in cell to cell
fusion (15). The 50% anticellular toxicity (TC50) of HS-1500
was found to be about 600 mg/ml in MT-2 cells by the
MTT assay (16). Comparison of this result with the IC50-
values (Table 1) yields a selectivity index (Sl; ratio of IC50
to TC50) of 2,000 (syncytium assay) to 12,000 (antigen
assay).
In quantitative terms HS-1500 resembles the most effi-
cient polyanionic polysaccharides such as dextran sul-
fate (13) and curdlan sulfate (17). In particular, HS-1500
inhibits HIV at least 10 times more efficiently and selec-
tively than the PHCs (11), although the compounds are
structurally related. Due to the chemical complexity of
these two groups of inhibitors, no correlations between
FIG. 1. Inactivation of HIV-1 virions before and after binding to targettheir chemical structure and efficacy can be drawn at
cells. (A) Pretreatment of the virus. The indicated dilutions of the HIV-present.
1IIIB virus stock were incubated with two concentrations of HS-1500 forTo study the influence of the synthetic humate on the
15 min at room temperature ( , mock-treated; , 0.4 mg/ml; and j,infectivity of HIV particles, three dilutions of the virus 40 mg/ml HS-1500). Virus was washed twice before determining the
stock in cell culture medium were treated with HS-1500 infectious units in aliquots of the resuspended virus pellet by the syncy-
tium assay. (B) Postbinding inhibition of HIV by HS-1500. MT-2 cellsand then separated from the inhibitor by sedimentation.
were incubated with 200-fold dilutions of virus stock at 07 ( or 377Separate sedimentation of either untreated virus or of
( ). Unbound virus was removed by washing of the cells. These wereHS-1500 only served as controls. Reduction of the viral
then incubated with the indicated concentrations of HS-1500 for 12 hr
infectivity was visualized by the syncytium assay. As and washed again. 1.25 1 104 cells were plated in triplicates into wells
shown in Fig. 1A, pretreatment of the virus for 30 min of microtiter plates and incubated without HS-1500 for 6 days followed
by counting of syncytia.with 0.4 mg/ml of HS-1500 reduced its syncytium inducing
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FIG. 2. Inhibition of HIV-envelope-induced syncytium formation. Gp120SU expressing CL4-cells (section 1) and HeLa-CD4 cells (section 2) were
incubated alone or mixed at a 2/1 ratio (section 3) and cultured for 20 hr without HS-1500 (sections 1–3). In the other mixed cultures (sections 4–
6) HS-1500 was present at 25, 12.5, or 6.25 mg/ml from the start of the coculture. Staining with hemocolor (Merck, Darmstadt) facilitated the detection
and counting of multinucleated giant cells.
To discriminate between interference at pre- and post- showed that a step of the infection process occurring
within the first hour after virus–cell attachment is inhibi-binding events, virus was incubated with MT-2 cells for
1 hr at 07, thus, allowing binding without entry (18). After tor sensitive. The presence of HS-1500 for 12 hr was
sufficient for inhibition, indicating, that the majority ofremoval of unbound virus, cells were treated with HS-
1500. The cells were further cultured at 377 for 12 hr in cell-attached virions were irreversibly inactivated. With
regard to IC50 , HS-1500 is equally effective irrespectivethe presence and then 6 days in the absence of inhibitor.
Incubation of cells and virus in the cold vs 377 reduced of its addition before or after binding of the virus to the
target cell (see Table 1). However, cell-attached virus isthe mean number of syncytia/well from 140 to 45 in the
inhibitor-free control cultures (not shown). As illustrated incompletely inhibited by 30 mg/ml of HS-1500, a concen-
tration sufficient to render cell-free virus preparationsin Fig. 1B, syncytium formation was suppressed to about
25% of the inhibitor-free cultures, when HS-1500 was noninfectious. Because in contrast to membrane fusion,
the CD4-induced conformational change of gp120SU isapplied after attachment of virus to the cells in the cold.
In contrast, incubation of the cells with virus for 1 hr at not influenced by low temperature (19), HS-1500 most
probably affects a later step of virus internalization.377 prior to treatment with HS-1500 only weakly affected
syncytium formation. This temperature shift experiment To further examine a potential direct effect of the inhibi-
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tor on the HIV-induced cell to cell fusion, interference
was studied in a virus-free model system (20). CD4-ex-
pressing HeLa cells (35) fuse with the HIV envelope pro-
tein expressing CL4 cells to form multinucleated syncytia
within 20 hr (Fig. 2, sections 1–3). Formation of syncytia
was completely inhibited at 25 mg/ml of HS-1500 (section
4). Sporadic syncytia were observed at 12.5 mg/ml (sec-
tion 5), and the inhibitory effect was diluted out at 6.25
mg/ml (section 6). Counting syncytia/well yielded an IC50
of about 10 mg/ml. This value is in the range of the IC50
(10–30 mg/ml) estimated for fusion of infected with unin-
fected cells (Table 1). Thus, fusion-inhibition is indepen-
dent of virus replication and cell type. Because in infec-
tion experiments treatment of the CD4-bearing target
cells failed to inhibit syncytium formation, this experiment
suggested an interaction of HS-1500 with the viral enve-
lope protein complex.
We therefore studied the binding of gp120SU to an
affinity matrix consisting of HS-1500 covalently coupled
to sepharose. Culture supernatants of radiolabeled H9/
HIV-1IIIB cells served as source of gp120SU. HIV-specific
polypeptides were immunoprecipitated by an HIV-spe-
cific serum (36) from the respective culture supernatants
before and after adsorption to HS-1500-sepharose. The
autoradiograph in Fig. 3A shows that serum from an
AIDS-patient immunoprecipitated polypeptides of about
120, 24, and 18 kDa from the unabsorbed supernatant
(lane 5), which represent the respective viral polypep-
tides gp120SU, p24CA, and p18MA of HIV. Absorption of
the culture fluid with HS-1500-bound sepharose prefer-
entially removed gp120SU (lane 1). The bands of the
other bona fide virion proteins of 18, 24, and 65 kDa are
also decreased, suggesting a certain degree of unspe-
cific binding. Absorption with humate-free sepharose had
no effect (lane 2). Normal control serum did not recognize
any polypeptide in the absorbed or unabsorbed culture
supernatants (lanes 3 and 4). Thus exhausting absorption
demonstrated that gp120SU selectively bound to HS- FIG. 3. Specific adsorption of gp120SU to HS-1500 sepharose. HS-
1500, whereas other immunoreactive HIV-polypeptides 1500 was covalently coupled to epoxy sepharose (Pharmacia, Freiburg,
Germany) as described by the manufacturer. Culture supernatant ofmainly remained in the supernatant. The excess of the
35S-cysteine-labeled HIV-1IIIB-infected H9 cells was preabsorbed withserum proteins from cell culture medium present during
HS-1500-sepharose (A, lanes 1 and 3) or uncoupled sepharose (A,binding supports the notion of selective binding of
lanes 2 and 4). Unabsorbed HIV-polypeptides were immunoprecipitated
gp120SU to HS-1500. To exclude a potential proteolysis with an AIDS-patient serum (A, lanes 1 and 2) or a negative control
or unspecific loss of gp120SU by incubation with HS- serum (A, lanes 3 and 4). For control, supernatant was immunoprecipi-
tated with the same sera prior to absorption (A, lanes 5, 6; B, lane 1).1500-sepharose, gp120SU was eluted from the affinity
HIV-polypeptides were eluted from HS-1500-sepharose by high saltmatrix and subsequently immunoprecipitated. Gp120SU
washing buffer (B, lane 2), 30% sucrose (B, lane 3), 0.5% desoxycholate,could be eluted from HS-1500-sepharose by high salt
and 0.5% NP-40 (B, lane 4), and 0.5 M NaCl (B, lane 5). Immunoprecipi-
washing buffer (Fig. 3B, lane 2), by its constituents NP- tates and a sample of the culture supernatant (A, lane 7) were analyzed
40 and desoxycholate (lane 4), and to a lesser extent by by SDS–PAGE and autoradiography.
0.5 M sodium chloride (lane 5), but not by 30% sucrose
(lane 3). Altogether these experiments demonstrate, that
soluble gp120SU binds reversibly to humate without im- interference with gp120-CD4 binding, nor by forced shed-
ding of gp120SU, since pretreatment of virus particlespairment of major antigenic determinants. The fact that
binding was reverted by detergents and high salt sug- with HS-1500 did not impair attachment of a recombinant
form of soluble CD4 (5) to virus or detection of gp120SUgests a hydrophobic and/or ionic nature of interaction.
The inactivation of the virion was neither caused by in virus pellets (data not shown). However, two indepen-
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FIG. 4. Interaction of HS-1500 with the V3 loop of gp120SU. (A) Permanent and dose-dependent inhibition of V3 loop-specific antibody binding.
HIV-1IIIB-infected H9 cells were treated with the indicated serial dilutions of humate, washed, and incubated individually with mouse monoclonal
antibodies specific for either the N-terminal part (NEA9284) or the b-turn of the V3 loop (NEA9305), for gp41 (NEA9303) or HLA-DQ (0416, Dianova
Hamburg); (NEA antibodies: DuPont, Bad Homburg). After staining with a FITC-labeled goat-anti-mouse antibody respective FITC-labeled donkey-
anti-human antibody for CD4-hg 1 (5), cells were characterized by FACS analysis. Medians of respective histograms are provided as a function of
HS-1500 concentrations. (B) Inhibition of the proteolytic cleavage of the V3 loop by HS-1500. HIV-1SF2 was incubated with rsCD4 and HS-1500,
followed by immunoblot analysis of the proteins gp120SU and p24CA as described previously. Lane 1, untreated virus; lane 2, virus with 20 ng of
rsCD4; lane 3 virus with 20 ng of rsCD4 and 20 mg/ml HS-1500; lanes 1–3 no incubation; lanes 4–13, virus with 20 ng of rsCD4 and 20, 10, 5, 2.5,
1.25, 0.6, 0.3, 0.15, 0.075 mg/ml HS-1500, or without inhibitor; lane 14, virus incubated without rsCD4 and HS-1500.
dent observations support the notion that HS-1500 inacti- weakly impaired at 50 mg/ml of HS-1500 (Fig. 4A). These
data illustrate that HS-1500 specifically suppressed thevated HIV mainly by binding to the V3 loop of gp120SU:
HS-1500 specifically prevented (i) the binding of antibod- recognition of V3-specific epitopes on infected cells in a
dose-dependent manner. Since the gp41TM-specific andies to the V3 loop and (ii) the proteolytic cleavage of the
V3 loop. HS-1500 significantly inhibited the binding of the V3 loop-specific antibodies are of the same murine
IgG subclass, a direct impairment of the reactivity of anti-the V3 loop-specific antibodies 9284 (21) and 9305 (22)
to HIV-infected H9 cells. In this assay, binding of recom- bodies by HS-1500 appears most unlikely. Because the
inhibitor-treated cells had been washed prior to incuba-binant soluble CD4 was slightly enhanced, the binding of
the gp41TM-specific antibody 9303 (23) was not affected, tion with the antibodies, HS-1500 seems to bind perma-
nently to the native form of gp120SU in the multimericand the reaction of the HLA-specific antibody was only
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envelope complex at the cell surface. The results of this polysaccharides tested so far fail to inactivate free virus
(17, 31, 32). Even the PHCs, which resemble HS-1500and the temperature shift experiment (Fig. 1B) suggest
that HS-1500 by binding to the V3 loop interferes with structurally, inhibit HIV by a different mechanism. Most
PHC preparations efficiently interfere with binding ofthe same function of gp120SU as V3 loop-specific anti-
bodies (24). gp120SU to CD4 and block the binding of virus to cells
completely (11), whereas HS-1500 slightly increases theIncubation of highly purified virions with soluble CD4
resulted in cleavage of the V3 loop by a protease inherent binding of recombinant soluble CD4 to HIV-infected cells
and mainly inactivates the virus particle.to these virus preparations. The cleavage could be
blocked by monoclonal antibodies to the crest of the V3 In conclusion, we describe the inhibition of HIV-1 by a
synthetic complex of compounds related to natural humicloop (25). Incubation of virus with soluble CD4 and HS-
1500 and subsequent analysis of viral proteins by immu- acids. Isolation of the active component(s) of the mixture
by affinity binding to V3 loop oligopeptides could yield anoblotting as described (25) demonstrated that the pres-
ence of HS-1500 interfered with the cleavage of gp120SU valuable tool to study the functions of the V3 loop within
the process of virus–cell fusion. Therapeutic approachesinto fragments of approximately 70 and 50 kDa (Fig. 4B).
Spontaneous cleavage was observed in the purified par- involving a mixture of closely related compounds rather
than a singular compound of defined chemical structureticles (Fig. 4B, lane 1) prior to incubation, and cleavage
was enhanced by incubation at 377 even without CD4 may represent a suitable strategy against a variable tar-
get such as HIV. The low toxicity of HS-1500 in various(lane 14). Due to this background, the efficacy of the
CD4-induced cleavage can be evaluated more precisely mammalian species (A. Haase, personal communication)
and lack of mutagenicity (U. N. Riede, unpublished) willfrom the decrease of the gp120SU band rather than from
the appearance of the cleavage products. Incubation of facilitate its evaluation in animal models for human AIDS.
the virus preparation with 20 ng of recombinant soluble
CD4 (rsCD4) yielded complete cleavage (lane 13). Addi- ACKNOWLEDGMENTS
tion of HS-1500 in twofold serial dilutions inhibited the We thank Monika Konanz for excellent technical assistance. We
cleavage in a dose-dependent manner with an IC50 be- are indebted to R. C. Gallo, M. Popovic, V. Bosch, K. Karjalainen, A.
Traunecker, and H.-J. Schlaeger for providing cell lines and to O. Hallertween 0.3 and 0.075 mg/ml. Thus, inhibition of the cleav-
and O. Herchenro¨der for critical reading of the manuscript. This workage and inhibition of HIV infectivity are observed at about
was supported by the Forschungsschwerpunkt Baden-Wu¨rttembergthe same concentration of HS-1500, which further sup-
(AZ II-7532).
ports the hypothesis that interaction of HS-1500 with the
V3 loop represents the predominant inhibition mecha-
REFERENCES
nism of the HS-1500 complex.
1. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard,In further support of a direct interaction of HS-1500
J. M., and Markowitz, M., Nature 373, 123–126 (1995).with the V3 loop, we observed a positive correlation be-
2. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A.,
tween the surplus of basic vs acidic amino acids in the Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn,
V3 loop and the sensitivity of individual virus isolates to B. H., Saag, M. S., and Shaw, G. M., Nature 373, 117–122 (1995).
3. Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H.,inhibition. Along this line, HS-1500 inactivated HIV-1IIIB
Greaves, M. F., and Weiss, R. A., Nature 312, 763–767 (1984).and HIV-1NDK with similar efficiency. The surplus of 9
4. Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard,basic amino acids is conserved in their V3 loops, while
D., Hercend, T., Gluckman, J. C., and Montagnier, L., Nature 312,
in the V3 loop amino acid sequences only 17 of 38 posi- 767–768 (1984).
tions are identical (26, 27). In agreement, HIV-1BaL , char- 5. Traunecker, A., Schneider, J., Kiefer, H., and Karjalainen, K., Nature
339, 68–70 (1989).acterized by a surplus of only 3 basic amino acids in the
6. McKeating, J. A., Gow, J., Goudsmit, J., Pearl, L. H., Mulder, C., andV3 loop, is inhibited at a 30–100 times higher IC50 al-
Weiss, R. A., AIDS 3, 777–784 (1989).though the V3 loop sequences of HIV-1BaL and HIV-1IIIB 7. Kliks, S. C., Shioda, T., Haigwood, N. L., and Levy, J. A., Proc. Natl.
are more closely related than those of HIV-1NDK and HIV- Acad. Sci. USA 90, 11518–11522 (1993).
1IIIB . These data also suggest that HS-1500 inhibits a 8. Daar, E. S., Li, X. L., Moudgil, T., and Ho, D. D., Proc. Natl. Acad.
Sci. USA 87, 6574–6578 (1990).broader range of HIV-isolates than the mainly type-spe-
9. De Clercq, E., Adv. Virus Res. 42, 1–55 (1993).cific V3 loop-reactive antibodies (28). Interestingly, the
10. Kutsch, H., and Schumacher, B., Biol. Fertil. Soils 18, 163–167high cytopathogenicity and efficient replication in lym-
(1994).
phocytes of HIV-1 isolates appears to be correlated to a 11. Schols, D., Wutzler, P., Klo¨cking, R., Helbig, B., and De Clercq, E.,
certain excess of basic vs acidic amino acids in the V3 J. AIDS 4, 677–685 (1991).
12. Schuitemaker, H., Koot, M., Kootstra, N. A., Dercksen, M. W.,loop (29, 30). Therefore, development of resistance to
De Goede, R. E., van Steenwijk, R. P., Lange, J. M., Schattenkerk,HS-1500 may select for HIV variants with low cytopatho-
J. K., Miedema, F., and Tersmette, M., J. Virol. 66, 1354–1360genicity.
(1992).
For other polyanionic HIV-inhibitors interaction with 13. Baba, M., Schols, D., Pauwels, R., Nakashima, H., and De Clercq,
the V3 loop is suggested as one of several potential E., J. AIDS 3, 493–499 (1990).
14. Pleskoff, O., Seman, M., and Alizon, M., J. Virol. 69, 570–574 (1995).mechanisms of HIV-inhibition. However, all polyanionic
AID VY 7839 / 6a13$$$662 03-14-96 09:31:13 vira AP: Virology
395SHORT COMMUNICATION
15. Pantaleo, G., Butini, L., Graziosi, C., Poli, G., Schnittman, S. M., Gallo, R. C., and Wong-Staal, F., AIDS Res. Hum. Retroviruses
3, 57–69 (1987).Greenhouse, J. J., Gallin, J. I., and Fauci, A. S., J. Exp. Med. 173,
511–514 (1991). 27. Spire, B., Sire, J., Zachar, V., Rey, F., Barre-Sinoussi, F., Galibert,
F. H., and Chermann, J. C., Gene 81, 275–284 (1989).16. Mosmann, T., J. Immunol. Methods 65, 55–63 (1983).
17. Jagodzinski, P. P., Wiaderkiewicz, R., Kurzawski, G., Kloczewiak, 28. Profy, A. T., Salinas, P. A., Eckler, L. I., Dunlop, N. M., Nara, P. L.,
and Putney, S. D., J. Immunol. 144, 4641–4647 (1990).M., Nakashima, H., Hyjek, E., Yamamoto, N., Uryu, T., Kaneko,
Y., Posner, M. R., and Kozbor, D., Virology 202, 735–745 (1994). 29. De Jong, J. J., De Ronde, A., Keulen, W., Tersmette, M., and Goud-
smit, J., J. Virol. 66, 6777–6780 (1992).18. Grewe, C., Beck, A., and Gelderblom, H. R., J. AIDS 3, 965–974
(1990). 30. Fouchier, R. A., Groenink, M., Kootstra, N. A., Tersmette, M., Huis-
man, H. G., Miedema, F., and Schuitemaker, H., J. Virol. 66,19. Sattentau, Q. J., and Moore, J. P., J. Exp. Med. 174, 407–415 (1991).
20. Kra¨usslich, H. G., Ochsenbauer, C., Traenckner, A. M., Mergener, 3183–3187 (1992).
31. McClure, M. O., Moore, J. P., Blanc, D. F., Scotting, P., Cook, G. M.,K., Fa¨cke, M. G., and Bosch, V., Virology 192, 605–617 (1993).
21. Skinner, M. A., Ting, R., Langlois, A. J., Weinhold, K. J., Lyerly, Keynes, R. J., Weber, J. N., Davies, D., and Weiss, R. A., AIDS
Res. Hum. Retroviruses 8, 19–26 (1992).H. K., Javaherian, K., and Matthews, T. J., AIDS Res. Hum. Retrovi-
ruses 4, 187–197 (1988). 32. Baba, M., Pauwels, R., Balzarini, J., Arnout, J., Desmyter, J., and
De Clercq, E., Proc. Natl. Acad. Sci. USA 85, 6132–6136 (1988).22. Matsushita, S., Robert-Guroff, M., Rusche, J., Koito, A., Hattori, T.,
Hoshino, H., Javaherian, K., Takatsuki, K., and Putney, S., J. Virol. 33. Miyoshi, I., Kubonishi, I., Yoshimoto, S., and Shiraishi, Y., Gann 72,
978–981 (1981).62, 2107–2114 (1988).
23. Jabbar, M. A., and Nayak, D. P., J. Virol. 64, 6297–6304 (1990). 34. Popovic, M., Read Connole, E., and Gallo, R. C., Lancet 2, 1472–
1473 (1984).24. Skinner, M. A., Langlois, A. J., McDanal, C. B., McDougal, J. S.,
Bolognesi, D. P., and Matthews, T. J., J. Virol. 62, 4195–4200 35. Maddon, P. J., McDougal, J. S., Clapham, P. R., Dalgleish, A. G.,
Jamal, S., and Weiss, R. A. A., Cell 54, 865–874 (1988).(1988).
25. Werner, A., and Levy, J. A., J. Virol. 67, 2566–2574 (1993). 36. Schneider, J., Kaaden, O., Copeland, T. D., Oroszlan, S., and Huns-
mann, G., J. Gen. Virol. 67, 2533–2538 (1986).26. Ratner, L., Fisher, A., Jagodzinski, L. L., Mitsuya, H., Liou, R. S.,
AID VY 7839 / 6a13$$$662 03-14-96 09:31:13 vira AP: Virology
